What can biomarkers tell us about cognition in Parkinson's disease?

Movement Disorders

Volumn 29, Issue 5, 2014, Pages 622-633

  Mollenhauer, Brit ^a   Rochester, Lynn ^b   Chen Plotkin, Alice ^c   Brooks, David ^d,e  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Biomarker; Blood; Cerebrospinal fluid; Dementia; Gait; Genetics; Imaging; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CATECHOL; CATECHOL METHYLTRANSFERASE; DOPAMINE TRANSPORTER; EPIDERMAL GROWTH FACTOR; GLUCOSYLCERAMIDASE; TAU PROTEIN; BIOLOGICAL MARKER;

CEREBROSPINAL FLUID; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; DISEASE MARKER; DOPAMINERGIC ACTIVITY; GAIT DISORDER; GENETIC MARKER; GLUCOSE METABOLISM; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; COGNITION; COGNITION DISORDERS; COMPLICATION; GENETIC VARIABILITY; GENETICS; METABOLISM; PHYSIOLOGY; RISK;

ANIMALS; BIOLOGICAL MARKERS; COGNITION; COGNITION DISORDERS; GENETIC VARIATION; HUMANS; PARKINSON DISEASE; RISK;

EID: 84898770196     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25846     Document Type: Review

References (136)

1. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-1263.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
3. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(pt 7):1787-1798.
4. Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011;26:289-296.
5. Melzer TR, Watts R, MacAskill MR, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:188-194.
6. Ibarretxe-Bilbao N, Junque C, Tolosa E, et al. Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease. Eur J Neurosci 2009;30:1162-1171.
7. Carlesimo GA, Piras F, Assogna F, Pontieri FE, Caltagirone C, Spalletta G. Hippocampal abnormalities and memory deficits in Parkinson disease: a multimodal imaging study. Neurology 2012;78:1939-1945.
8. Vander-Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J Nucl Med 1997;38:797-802.
9. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14:1357-1362.
10. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70(16 pt 2):1470-1477.
11. Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined 31Phosphorus MRS and 18FDG PET study. Brain 2000;123:340-352.
12. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011;52:848-855.
13. Rektorova I, Krajcovicova L, Marecek R, Mikl M. Default mode network and extrastriate visual resting state network in patients with Parkinson's disease dementia. Neurodegener Dis 2012;10(1-4):232-237.
14. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-1181.
15. Arnaldi D, Morbelli S, Morrone E, Campus C, Nobili F. Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging. Q J Nucl Med Mol Imaging 2012;56:55-67.
16. Ito K, Nagano-Saito A, Kato T, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002;125(pt 6):1358-1365.
17. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74:885-892.
18. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399-410.
19. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-1722.
20. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253:242-247.
21. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-434.
22. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
23. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-910.
24. Jokinen P, Scheinin N, Aalto S, et al. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010;16:666-670.
25. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
26. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-1410.
27. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134(pt 5):1493-1505.
28. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012;27:965-973.
29. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91.
30. Eberling JL, Dave KD, Frasier MA. α-Synuclein imaging: a critical need for Parkinson's disease research. J Parkinsons Dis 2013;3:565-567.
31. Boche D, Perry VH, Nicoll JA. Activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 2013;39:3-18.
32. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-175.
33. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006;21:404-412.
34. Simpson BS, Pavese N, Ramlackhansingh AF, Breen DP, Barker RA, Brooks DJ. Clinical correlates of brain inflammation in Parkinson's disease: a PET study [abstract]. Mov Disord 2012;27(suppl 1):775.
35. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013;38:938-949.
36. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 2001;310:173-186.
37. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 1984;2:357-369.
38. Jendroska K, Kashiwagi M, Sassoon J, Daniel SE. Amyloid beta-peptide and its relationship with dementia in Lewy body disease. J Neural Transm Suppl 1997;51:137-144.
39. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
40. Mollenhauer B, Esselmann H, Roeber S, et al. Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm 2011;118:691-697.
41. Kanemaru K, Kameda N, Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000;54:1875-1876.
42. Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson's disease: the ICICLE-PD Study. Neurology 2014;82:308-316.
43. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200-208.
44. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186-190.
45. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
46. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian Park West study. J Neurol Neurosurg Psychiatry 2010;81:1080-1086.
47. Bibl M, Mollenhauer B, Lewczuk P, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007;12:671-680.
48. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986;261:6084-6089.
49. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001;24:1121-1159.
50. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-526.
51. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187-190.
52. Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006;63:1277-1280.
53. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-245.
54. Mollenhauer B, Cepek L, Bibl M, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005;19(2-3):164-170.
55. Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull 2003;61:243-253.
56. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586-1590.
57. Arima K, Hirai S, Sunohara N, et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 1999;843(1-2):53-61.
58. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64:850-855.
59. Luk C, Compta Y, Magdalinou N, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012;123:396-405.
60. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945-1947.
61. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-6024.
62. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580.
63. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012;33:430.e1-430.e3.
64. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010;4:683-699.
65. Kang JH, Irwin DJ, Chen-Plotkin A, et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease [published online ahead of print 26 August 2013]. JAMA Neurol.
66. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol 2013;126:683-697.
67. Larson ME, Sherman MA, Greimel S, et al. Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 2012;32:10253-10266.
68. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-1772.
69. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
70. Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011;69:655-663.
71. Pellecchia MT, Santangelo G, Picillo M, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. J Neurol 2013;260:438-444.
72. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 2010;4:701-712.
73. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 2008;14:576-578.
74. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, Diaz-Arrasyia R. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-868.
75. Mollenhauer B, Steinacker P, Bahn E, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 2007;4:366-375.
76. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol 2010;119:703-713.
77. Devic I, Hwang H, Edgar JS, et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease [serial online]. Brain 2011;134(pt 7):e178.
78. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. JAMA 1995;274:1627-1629.
79. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79:458-461.
80. Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006;21:45-49.
81. Ryu HG, Kwon OD. Apolipoprotein E epsilon 4 allele is not associated with age at onset or MMSE of Parkinson's disease in a Korean study. Parkinsonism Relat Disord 2010;16:615-617.
82. Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology 1994;44:1330-1331.
83. Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. Neurosci Lett 2008;448:20-23.
84. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54:1272-1276.
85. Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009;256:493-498.
86. Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson's disease. Mov Disord 2012;27:512-518.
87. Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007;27:4832-4838.
88. Hoogland J, de Bie RM, Williams-Gray CH, Muslimovic D, Schmand B, Post B. Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease. Mov Disord 2010;25:2550-2554.
89. Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative disorders. Hum Mol Genet 2006;15(spec no 2):R188-R195.
90. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007;62:145-153.
91. Seto-Salvia N, Clarimon J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 2011;68:359-364.
92. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
93. Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 2013;70:852-858.
94. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78(18):1434-1440.
95. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011;305:50-58.
96. Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc 2012;60:2127-2136.
97. Bohnen N, Jahn K. Imaging: what can it tell us about Parkinsonian gait? Mov Disord 2013;28:1492-1500.
98. Takakusaki K. Neurophysiology of gait: from the spinal cord to the frontal lobe. Mov Disord 2013;28:1483-1491.
99. Amboni M, Braone P, Hausdorff J. Cognitive contributions to gait and falls: evidence and implications. Mov Disord 2013;28:1520-1533.
100. Lord S, Galna B, Rochester L. Moving forward on gait measurement: toward a more refined approach. Mov Disord 2013;28:1534-1543.
101. Miekle MM, Roberts RO, Savica R, et al. Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 2013;68:929-937.
102. Lord S, Galna B, Verghese J, Coleman S, Burn D, Rochester L. Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci 2013;68:820-827.
103. Verlinden VJ, van der Geest JN, Hofman A, Ikram MA. Cognition and gait show a distinct pattern of association in the general population [published online ahead of print 9 July 2013]. Alzheimers Dement.
104. Martin KL, Blizzard L, Wood AG, Srikanth V, Thomson R, Sanders LM, Callisaya ML. Cognitive function, gait and gait variability in older people: a population-based study. J Gerontol A Biol Sci Med Sci 2013;68:726-732.
105. Buracchio T, Dodge HH, Howieson D, Wasserman D, Kaye J. The trajectory of gait speed preceding mild cognitive impairment. Arch Neurol 2010;67:980-986.
106. Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry 2007;78:929-935.
107. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127(pt 3):550-560.
108. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers and treatment. Lancet Neurol 2012;11:697-707.
109. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-1213.
110. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132(pt 11):2958-2969.
111. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003;18:884-889.
112. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:585-589.
113. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123-1130.
114. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology 2005;65:1907-1913.
115. Domellof M, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. Mov Disord 2011;26:2183-2189.
116. Lord S, Baker K, Nieuwboer A, Burn D, Rochester L. Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol 2011;258:566-572.
117. Lord S, Rochester L, Hetherington V, Allcock LM, Burn D. Executive dysfunction and attention contribute to gait interference in "off" state Parkinson's disease. Gait Posture 2010;31:169-174.
118. Rochester L, Nieuwboer A, Baker K, et al. Walking speed during single and dual tasks in Parkinson's disease: which characteristics are important? Mov Disord 2008;23:2312-2318.
119. Yogev G, Giladi N, Peretz C, Springer S, Simon ES, Hausdorff JM. Dual tasking, gait rhythmicity, and Parkinson's disease: which aspects of gait are attention demanding? Eur J Neurosci 2005;22:1248-1256.
120. Amboni M, Barone P, Iuppariello L, et al. Gait patterns in Parkinsonian patients with or without mild cognitive impairment. Mov Disord 2012;27:1536-1543.
121. Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson's disease correlates with cholinergic degeneration. Neurology 2013;81:1611-1616.
122. Rochester L, Yarnall AJ, Baker MR, David RV, Lord S, Galna B, Burn DJ. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012;135(pt 9):2779-2788.
123. Muller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, Bohnen NI. β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013;28:296-301.
124. Alves G, Pedersen KF, Bloem BR, et al. Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:537-543.
125. Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol 2011;7:229-236.
126. Holtzer R, Ozelius L, Xue X, Wang T, Lipton RB, Verghese J. Differential effects of COMT on gait and executive control in aging. Neurobiol Aging 2010;31:523-531.
127. Verghese J, Holtzer R, Wang C, Katz M, Barzilai N, Lipton R. Role of APOE genotype in gait decline and disability in aging. J Gerontol A Biol Sci Med Sci 2013;68:1395-1401.
128. Olde Dubbelink KT, Hillebrand A, Twisk JW, et al. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology 2014;82:263-270.
129. Yarnall AJ, Rochester L, Baker MR, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease? Mov Disord 2013;28:1285-1288.
130. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008;131(pt 3):690-705.
131. Klassen BT, Hentz JG, Shill HA, et al. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology 2011;77:118-124.
132. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009;66:39-47.
133. Baba T, Kikuchi A, Hirayama K, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 2012;135(pt 1):161-169.
134. Stephenson R, Houghton D, Sundarararjan S, et al. Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease. Mov Disord 2010;25:2099-2104.
135. Mollenhauer B, Schulz-Schaeffer W, Schlossmacher M. Synaptic alpha-synuclein pathology as the likely cause of Parkinson's disease dementia. Lancet Neurol 2011;10:68-69.
136. Weinrich C, Wrede A, Mollenhauer B. [Analysis of cerebrospinal fluid proteins in the diagnosis of Parkinson's disease, Parkinson dementia and dementia with Lewy bodies.] Akt Neural 2011;38:203-210.